Please provide your email address to receive an email when new articles are posted on . In adults with Graves’ disease, the risk for Graves’ orbitopathy may be associated with increased levels of ...

To identify the predictive factors for overcorrection and depression impairment after recession of the inferior rectus muscle (IRM) in patients with Graves’ orbitopathy. The charts of 124 consecutive ...

Selenium supplementation is widely used for a broad range of autoimmune thyroid diseases, although it is only recommended for mild Graves’ orbitopathy. One study found that patients treated with ...

VICTORIA, British Columbia — The addition of nonsteroidal intravenous (IV) mycophenolate to the recommended therapy of IV methylprednisolone significantly improves severe Graves' orbitopathy, with ...

Background A 59-year-old woman with a history of nodular goiter developed thyrotoxic symptoms while on levothyroxine therapy. Her thyrotoxicosis persisted after levothyroxine withdrawal, so she was ...

SAN DIEGO — Double vision is the predominant symptom in more than half of patients with moderate to severe Graves' orbitopathy; however, the symptom negatively correlates with inflammation and in fact ...

Radioactive iodine (RAI) treatment was associated with an increased risk of developing Graves' orbitopathy (GO) in patients with thyroid cancer. Patients who developed GO received significantly higher ...

Most people associate thyroid disorders with weight changes, fatigue, or hair loss. What rarely makes it into that conversation is the eye. Yet for a significant number of patients, particularly those ...

Graves’ disease is the most common cause of hyperthyroid­ism and frequently causes changes to the eye and surrounding structures, including retraction of the eyelid, bulging of the eye, and restricted ...

Thyroid Eye Disease (TED), also known as Graves' ophthalmopathy or Graves' orbitopathy, is an autoimmune condition that affects the eyes of individuals with an overactive thyroid (hyperthyroidism) ...

Current treatments for Graves’ hyperthyroidism (GH) and Graves’ orbitopathy (GO) are ineffective. Researchers assessed the preclinical in vitro efficacy of SYD-5115 (Byondis BV), a novel low-molecular ...